Fabienne Meier-Abt

Fabienne Meier-Abt

Auto-generated profile, based on publicly available information

Fabienne Meier-Abt

Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Blood
Verified
Journal Article
Open access
PDF file
NMNicole Mende
Nicole Mende
HBHugo P. Bastos
Hugo P. Bastos
ASAntonella Santoro
Antonella Santoro
KMKrishnaa T. Mahbubani
Krishnaa T. Mahbubani
VCValerio Ciaurro
Valerio Ciaurro
ELElisa Laurenti
Elisa Laurenti
Rare hematopoietic stem and progenitor cell (HSPC) pools outside the bone marrow (BM) contribute to blood production in stress and disease but remain ill-defined. Although nonmobilized peripheral blood (PB) is routinely sampled for clinical management, the diagnosis and monitoring potential of PB HSPCs remain untapped, as no healthy PB HSPC baseline has been reported. Here we comprehensively delineate human extramedullary HSPC compartments comparing spleen, PB, and mobilized PB to BM using single-cell RNA-sequencing and/or functional assays. We uncovered HSPC features shared by extramedullary tissues and others unique to PB. First, in contrast to actively dividing BM HSPCs, we found no evidence of substantial ongoing hematopoiesis in extramedullary tissues at steady state but report increased splenic HSPC proliferative output during stress erythropoiesis. Second, extramedullary hematopoietic stem cells/multipotent progenitors (HSCs/MPPs) from spleen, PB, and mobilized PB share a common transcriptional signature and increased abundance of lineage-primed subsets compared with BM. Third, healthy PB HSPCs display a unique bias toward erythroid-megakaryocytic differentiation. At the HSC/MPP level, this is functionally imparted by a subset of phenotypic CD71+ HSCs/MPPs, exclusively producing erythrocytes and megakaryocytes, highly abundant in PB but rare in other adult tissues. Finally, the unique erythroid-megakaryocytic–skewing of PB is perturbed with age in essential thrombocythemia and β-thalassemia. Collectively, we identify extramedullary lineage-primed HSPC reservoirs that are nonproliferative in situ and report involvement of splenic HSPCs during demand-adapted hematopoiesis. Our data also establish aberrant composition and function of circulating HSPCs as potential clinical indicators of BM dysfunction.

16 December 2021 in Blood
Verified
Journal Article
Open access
PDF file
FMFabienne Meier-Abt
Fabienne Meier-Abt
JLJunyan Lu
Junyan Lu
ECEster Cannizzaro
Ester Cannizzaro
MPMarcel F. Pohly
Marcel F. Pohly
SKSandra Kummer
Sandra Kummer
TZThorsten Zenz
Thorsten Zenz
Many functional consequences of mutations on tumor phenotypes in chronic lymphocytic leukemia (CLL) are unknown. This may be in part due to a scarcity of information on the proteome of CLL. We profiled the proteome of 117 CLL patient samples with data-independent acquisition mass spectrometry and integrated the results with genomic, transcriptomic, ex vivo drug response, and clinical outcome data. We found trisomy 12, IGHV mutational status, mutated SF3B1, trisomy 19, del(17)(p13), del(11)(q22.3), mutated DDX3X and MED12 to influence protein expression (false discovery rate [FDR] = 5%). Trisomy 12 and IGHV status were the major determinants of protein expression variation in CLL as shown by principal-component analysis (1055 and 542 differentially expressed proteins, FDR = 5%). Gene set enrichment analyses of CLL with trisomy 12 implicated B-cell receptor (BCR)/phosphatidylinositol 3-kinase (PI3K)/AKT signaling as a tumor driver. These findings were supported by analyses of protein abundance buffering and protein complex formation, which identified limited protein abundance buffering and an upregulated protein complex involved in BCR, AKT, MAPK, and PI3K signaling in trisomy 12 CLL. A survey of proteins associated with trisomy 12/IGHV-independent drug response linked STAT2 protein expression with response to kinase inhibitors, including Bruton tyrosine kinase and mitogen-activated protein kinase kinase (MEK) inhibitors. STAT2 was upregulated in unmutated IGHV CLL and trisomy 12 CLL and required for chemokine/cytokine signaling (interferon response). This study highlights the importance of protein abundance data as a nonredundant layer of information in tumor biology and provides a protein expression reference map for CLL.

11 February 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
FMFabienne Meier-Abt
Fabienne Meier-Abt
WWWitold E. Wolski
Witold E. Wolski
GTGe Tan
Ge Tan
SKSandra Kummer
Sandra Kummer
SASabine Amon
Sabine Amon
ATAlexandre P. A. Theocharides
Alexandre P. A. Theocharides

1 May 2021 in Experimental Hematology
Verified
Journal Article
Open access
GTGe Tan
Ge Tan
FMFabienne Meier-Abt
Fabienne Meier-Abt
Polycythemia vera (PV) is a myeloproliferative neoplasm marked by hyperproliferation of the myeloid lineages and the presence of an activating JAK2 mutation. Hydroxyurea (HU) is a standard treatment for high-risk PV patients. Since disease-driving mechanisms are thought to arise in PV stem cells, effective treatments should primarily target the stem cell compartment. We tested for the anti-proliferative effect of patient treatment with HU in FACS-isolated hematopoietic stem/multipotent progenitor cells (HSC/MPPs) and more committed erythroid progenitors (CMP/MEPs) in PV using RNA-sequencing and gene set enrichment analysis. HU treatment led to significant downregulation of gene sets associated with cell proliferation in PV HSC/MPPs, but not in PV CMP/MEPs. To explore the mechanism underlying this finding, we assessed for expression of solute carrier membrane transporters, which mediate transmembrane movement of drugs like HU into target cells. The active HU uptake transporter OCTN1 was upregulated in HSC/MPPs compared to CMP/MEPs of untreated PV patients, and the HU diffusion facilitator UTB was downregulated in HSC/MPPs compared to CMP/MEPs in all tested patient and control groups. These findings indicate a higher accumulation of HU within PV HSC/MPPs compared to PV CMP/MEPs and provide an explanation for the differential effects of HU in HSC/MPPs and CMP/MEPs of PV patients. In general, the findings highlight the importance of transporter expression in linking therapeutics with human disease.

10 June 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
GTGe Tan
Ge Tan
WWWitold Eryk Wolski
Witold Eryk Wolski
SKSandra Kummer
Sandra Kummer
MHMara Carina Hofstetter
Mara Carina Hofstetter
ATAlexandre P. A. Theocharides
Alexandre P. A. Theocharides
FMFabienne Meier-Abt
Fabienne Meier-Abt
Polycythemia vera (PV) is a stem cell disorder characterized by hyperproliferation of the myeloid lineages and the presence of an activating JAK2 mutation. To elucidate mechanisms controlling PV stem and progenitor cell biology, we applied a recently developed highly sensitive data-independent acquisition mass spectrometry workflow to purified hematopoietic stem and progenitor cell (HSPC) subpopulations of patients with chronic and progressed PV. We integrated proteomic data with genomic, transcriptomic, flow cytometry, and in vitro colony formation data. Comparative analyses revealed added information gained by proteomic compared with transcriptomic data in 30% of proteins with changed expression in PV patients. Upregulated biological pathways in hematopoietic stem and multipotent progenitor cells (HSC/MPPs) of PV included mammalian target of rapamycin (MTOR), STAT, and interferon signaling. We further identified a prominent reduction of clusterin (CLU) protein expression and a corresponding activation of nuclear factor-κB (NF-κB) signaling in HSC/MPPs of untreated PV patients compared with controls. Reversing the reduction of CLU and inhibiting NF-κB signaling decreased proliferation and differentiation of PV HSC/MPPs in vitro. Upon progression of PV, we identified upregulation of LGALS9 and SOCS2 protein expression in HSC/MPPs. Treatment of patients with hydroxyurea normalized the expression of CLU and NF-κB2 but not of LGALS9 and SOCS2. These findings expand the current understanding of the molecular pathophysiology underlying PV and provide new potential targets (CLU and NF-κB) for antiproliferative therapy in patients with PV.

2 January 2024 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
FMFabienne Meier‐Abt
Fabienne Meier‐Abt
DKDennis Kraemer
Dennis Kraemer
NBNils Braun
Nils Braun
MRMichael Reinehr
Michael Reinehr
ESEveline Stutz‐Grunder
Eveline Stutz‐Grunder
ARAnita Rauch
Anita Rauch
Somatic variants in the NOTCH pathway regulator FBXW7 are frequently seen in a variety of malignancies. Heterozygous loss‐of‐function germline variants in FBXW7 have recently been described as causative for a neurodevelopmental syndrome. Independently, FBXW7 was also considered as a susceptibility gene for Wilms tumor due to a few observations of heterozygous germline variants in patients with Wilms tumor. Whether the same FBXW7 variants are implicated in both, neurodevelopmental delay and Wilms tumor formation, remained unclear. By clinical testing, we now observed a patient with neurodevelopmental delay due to a de novo constitutional mosaic FBXW7 splice site pathogenic variant who developed Wilms tumor. In the tumor, we identified a second hit frameshift variant in FBXW7. Immunohistochemical staining was consistent with mosaic loss of FBXW7 protein expression in the tumor. Our data support the role of constitutional FBXW7 pathogenic variants in both, neurodevelopmental disorder and the etiology of Wilms tumor. Therefore, Wilms tumor screening should be considered in individuals with constitutional or germline pathogenic variants in FBXW7 and associated neurodevelopmental syndrome.